Meetings of the International Civil Aviation Organization (ICAO) during the Mpox Public Health Emergency

The International Civil Aviation Organization (ICAO) has reviewed the World Health Organization (WHO) guidelines regarding public gatherings in light of the current Mpox outbreak: Public health advice for gatherings during the current Mpox outbreak (who.int).

As of 19 August 2024, and based on a thorough risk assessment of current available information, ICAO has determined that there is no necessity to postpone or cancel its scheduled meetings. The Organization will continue to monitor the situation and adhere to the advice of WHO for Member States, authorities and event organizers. This includes implementing preventive and management measures for mpox through collaboration between the ICAO Medical Services and the Canadian Public Health Authority.

In addition, ICAO has revised its risk mitigation strategies in line with the United Nations Medical Directors’ Risk Mitigation Plan for Mpox to further ensure the safety of all participants.

ACTIONS BY MEETING PARTICIPANTS

Do not attend a meeting should they exhibit any signs or symptoms compatible with mpox.
Seek immediate medical attention and notify ICAO Medical Services without delay by contacting +1 (514) 315-1955 or medcen [at] icao.int (medcen[at]icao[dot]int), should they develop any signs or symptoms compatible.
Avoid close contact with individuals showing signs or symptoms compatible with mpox.
Utilize hand disinfection stations provided throughout the ICAO premises.

Note 1. Signs and symptoms: Mpox symptoms may include a skin rash on the face, hands, and feet, acute fever (>38.5°C), swollen lymph nodes, headache, muscle aches, back pain, severe weakness and extreme fatigue.

Note 2. Face masks: Currently, there are no recommendations or requirements for wearing face masks for mpox as it has not been recommended by WHO for mpox. The decision to wear a mask is left to individual discretion as it could mitigate the transmission of other airborne infections or protect high-risk individuals.

Note 3. Mass vaccination: It is not recommended for mpox currently. WHO’s guidance on mpox vaccination is available here.